Although antivascular
endothelial growth factor a (VEGFa) treatment has been well applied in
cervical cancer therapy, the underlying molecular basis has not been precisely identified. Here, we examined the levels of VEGFa on the
tumor growth and invasion in four commonly used human
cervical cancer cell lines. We found that overexpression of VEGFa in these lines increased the
tumor growth and invasiveness, while inhibition of VEGFa decreased the
tumor growth and invasiveness. To figure out the involved signaling pathways, we applied specific inhibitors for ERK/MAPK, JNK, and PI3K/Akt signaling pathways, respectively, to VEGFa-overexpressing
cervical cancer lines and found that only inhibition of PI3K/Akt signal transduction abolished VEGFa-induced increases in cell growth and invasiveness. Inhibition of Akt downstream mTor signaling similarly inhibited cell growth and invasion in VEGFa-overexpressing
cervical cancer cells, suggesting that VEGFa may activate PI3K/Akt, and subsequently its downstream mTor signaling pathway, to promote
cervical cancer cell growth and invasion. Furthermore, the effects of VEGFa-induced activation of mTor signaling cascades appeared to promote
cancer cell growth through cyclinD1 and CDK4 activation and promote
cancer cell invasion through MMP2 and MMP3. Taken together, our data suggest that anti-VEGFa treatment in
cervical cancer may inhibit both
tumor cell growth and invasion through PI3k/Akt/mTor signaling pathway.